Arcoma

Arcoma EBIT Growth

The Year-over-Year EBIT Growth of Arcoma (ARCOMA.ST) as of Oct 24, 2026 is -38.10 %. In the previous year, Year-over-Year EBIT Growth was 201.03 % — a change of -118.95% (lower).

EBIT Growth

-38.10 %

YoY

-118.95%

Last updated:

Year-over-Year EBIT Growth of Arcoma is 2025 -38.10 % . Year-over-Year EBIT Growth of Arcoma was 2024 201.03 % . It decreases by -118.95% lower compared to the previous year.

The Arcoma EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
95.67 SEK
Jan 1, 2019
2,201.39 SEK
Jan 1, 2020
-74.87 SEK
Jan 1, 2021
-456.62 SEK
Jan 1, 2022
138.32 SEK
Jan 1, 2023
49.12 SEK
Jan 1, 2024
201.03 SEK
Jan 1, 2025
-38.10 SEK
The Arcoma EBIT Growth history
YEAREBIT GrowthYoY
-38.10 %-118.95%
201.03 %+309.26%
49.12 %-64.49%
138.32 %-130.29%
-456.62 %+509.93%
-74.87 %-103.40%
2,201.39 %+2,201.11%
95.67 %+326.62%
22.42 %-120.80%
-107.79 %-90.85%
-1,177.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Year-over-Year EBIT Growth of Arcoma is -38.10 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Arcoma since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Arcoma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Arcoma

All Key Metrics — Arcoma